A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Carcinoma, Pancreatic Ductal
/ blood
Early Detection of Cancer
/ methods
Female
Genetic Predisposition to Disease
Genomics
Humans
Life Style
Male
Metabolic Diseases
/ blood
Metabolomics
Middle Aged
Pancreatic Neoplasms
/ blood
Predictive Value of Tests
Risk Assessment
Risk Factors
biomarkers
early diagnosis
metabolomics
pancreatic ductal adenocarcinoma
proteomics
risk factors
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
12
10
2018
revised:
09
12
2018
accepted:
12
12
2018
pubmed:
15
12
2018
medline:
31
7
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
We aimed to review the epidemiologic literature examining lifestyle and metabolic risk factors, and blood-based biomarkers including multi-omics (genomics, proteomics, and metabolomics) and to discuss how these predictive markers can inform early diagnosis of pancreatic ductal adenocarcinoma (PDAC). A search of the PubMed database was conducted in June 2018 to review epidemiologic studies of (i) lifestyle and metabolic risk factors for PDAC, genome-wide association studies, and risk prediction models incorporating these factors and (ii) blood-based biomarkers for PDAC (conventional diagnostic markers, metabolomics, and proteomics). Prospective cohort studies have reported at least 20 possible risk factors for PDAC, including smoking, heavy alcohol drinking, adiposity, diabetes, and pancreatitis, but the relative risks and population attributable fractions of individual risk factors are small (mostly < 10%). High-throughput technologies have continued to yield promising genetic, metabolic, and protein biomarkers in addition to conventional biomarkers such as carbohydrate antigen 19-9. Nonetheless, most studies have utilized a hospital-based case-control design, and the diagnostic accuracy is low in studies that collected pre-diagnostic samples. Risk prediction models incorporating lifestyle and metabolic factors as well as other clinical parameters have shown good discrimination and calibration. Combination of traditional risk factors, genomics, and blood-based biomarkers can help identify high-risk populations and inform clinical decisions. Multi-omics investigations can provide valuable insights into disease etiology, but prospective cohort studies that collect pre-diagnostic samples and validation in independent studies are warranted.
Identifiants
pubmed: 30550622
doi: 10.1111/jgh.14576
pmc: PMC6378598
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
330-345Subventions
Organisme : Wellcome Trust
ID : 212946/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12026/2
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/23/33512
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00017/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137686851
Pays : United Kingdom
Informations de copyright
© 2018 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Proteomics. 2014 Mar;14(6):774-83
pubmed: 24520068
Gastroenterology. 2013 Jun;144(6):1252-61
pubmed: 23622135
Lancet Oncol. 2009 Jan;10(1):88-95
pubmed: 19111249
Proteomics. 2008 Jun;8(11):2211-9
pubmed: 18528842
PLoS One. 2013 Sep 13;8(9):e72311
pubmed: 24058443
Cancer Res. 2012 May 15;72(10):2481-90
pubmed: 22589272
Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):359-69
pubmed: 21173171
Int J Cancer. 2018 Nov 1;143(9):2161-2167
pubmed: 29717485
Sci Transl Med. 2015 Jun 24;7(293):293ra104
pubmed: 26109104
PLoS One. 2010 Jul 29;5(7):e11824
pubmed: 20686608
Br J Cancer. 2012 Feb 28;106(5):1004-10
pubmed: 22315049
Clin Cancer Res. 2015 Feb 1;21(3):622-31
pubmed: 24938522
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):438-44
pubmed: 15006921
Langenbecks Arch Surg. 2008 Jul;393(4):535-45
pubmed: 18193270
Nat Rev Gastroenterol Hepatol. 2013 Jul;10(7):423-33
pubmed: 23528347
Nat Rev Genet. 2016 Jul;17(7):392-406
pubmed: 27140283
J Clin Gastroenterol. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and:S82-S85
pubmed: 30001289
Curr Mol Med. 2013 Mar;13(3):340-51
pubmed: 23331006
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Nat Med. 2014 Oct;20(10):1193-1198
pubmed: 25261994
J Clin Oncol. 2007 Apr 10;25(11):1417-22
pubmed: 17416862
Am J Cancer Res. 2018 Mar 01;8(3):332-353
pubmed: 29636993
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):855-61
pubmed: 23462920
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28954281
Ann Oncol. 2010 Mar;21(3):441-447
pubmed: 19690057
Int J Epidemiol. 2015 Feb;44(1):186-98
pubmed: 25502106
J Gastroenterol Hepatol. 2019 Feb;34(2):330-345
pubmed: 30550622
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207
pubmed: 28874546
Mol Oncol. 2016 Oct;10(8):1305-16
pubmed: 27522951
J Epidemiol Community Health. 2017 Nov;71(11):1059-1067
pubmed: 28900029
Int J Cancer. 2017 Jul 15;141(2):231-241
pubmed: 28240774
Int J Epidemiol. 2003 Feb;32(1):1-22
pubmed: 12689998
Circ Cardiovasc Genet. 2015 Feb;8(1):192-206
pubmed: 25691689
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Br J Cancer. 2012 May 22;106(11):1866-74
pubmed: 22617158
PLoS One. 2014 Apr 18;9(4):e94928
pubmed: 24747429
Ann Oncol. 2017 May 1;28(5):985-995
pubmed: 28453689
J Cancer Res Clin Oncol. 2011 Mar;137(3):375-89
pubmed: 21193998
Int J Cancer. 2017 Apr 15;140(8):1781-1788
pubmed: 28063165
Cancer Res. 2007 Aug 15;67(16):7923-8
pubmed: 17699799
Int J Proteomics. 2015;2015:587250
pubmed: 26587286
Clin Cancer Res. 2015 Apr 1;21(7):1764-71
pubmed: 25589628
Int J Cancer. 2010 Mar 15;126(6):1474-86
pubmed: 19816941
Gut. 2018 Jan;67(1):128-137
pubmed: 28108468
Br J Cancer. 2007 Jul 2;97(1):98-104
pubmed: 17533398
PLoS Med. 2009 Apr 7;6(4):e1000046
pubmed: 19360088
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Ann Oncol. 2012 Nov;23(11):2964-2970
pubmed: 22767586
Am J Gastroenterol. 2017 Jan;112(1):172-183
pubmed: 27845339
Nat Genet. 2011 Dec 11;44(1):62-6
pubmed: 22158540
PLoS One. 2016 Jan 11;11(1):e0146473
pubmed: 26752291
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Am J Epidemiol. 2014 Jul 15;180(2):129-39
pubmed: 24966222
BMJ Open. 2015 Mar 17;5(3):e007825
pubmed: 25783428
Eur J Epidemiol. 2015 Apr;30(4):279-98
pubmed: 25773752
Gastroenterology. 2017 Mar;152(4):840-850.e3
pubmed: 27923728
J Clin Epidemiol. 2004 Apr;57(4):332-40
pubmed: 15135833
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
Clin Cancer Res. 2016 Apr 1;22(7):1734-1743
pubmed: 26573598
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Nat Rev Cancer. 2017 Mar;17(3):199-204
pubmed: 28154374
JAMA. 2005 Dec 14;294(22):2872-8
pubmed: 16352795
Gastroenterology. 2008 Apr;134(4):981-7
pubmed: 18395079
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Cancer Sci. 2018 May;109(5):1672-1681
pubmed: 29575390
Clin Cancer Res. 2011 Feb 15;17(4):805-16
pubmed: 21325298
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35
pubmed: 23847240
Ann Oncol. 2012 Apr;23(4):843-52
pubmed: 21890910
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2298-306
pubmed: 20699371
Am J Epidemiol. 2015 Jul 1;182(1):26-34
pubmed: 26049860
Eur J Surg Oncol. 2007 Apr;33(3):266-70
pubmed: 17097848